# US 4,400,383 A · Treatment of anxiety

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 4,400,383 A
- Document ID: US4400383A
- Status: Granted
- Kind: A
- Application number: 06/413,078
- Filed: 1982-08-30
- Granted: 1983-08-23
- Earliest claimed: 1981-12-11
- Assignees: Burroughs Wellcome Co.
- Inventors: Jonathan R. T. Davidson; Anthony T. Dren
- Web page: https://patentgrep.com/patent/US4400383A

## CPC

- C07D 209/86: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This invention is directed to the use of a carbazole compound 9-[3-(3,5-cis-dimethylpiperazino)propyl]carbazole, its salts, especially pharmaceutically acceptable salts, and solvates such as hydrates, alcoholates of the salts thereof as well as pharmaceutical compositions containing same in treating anxiety such as generalized anxiety disorder, etc., in humans.

## Claims

### Claim 1

The method of treating generalized anxiety disorder anxiety in a human which has been identified as exhibiting generalized anxiety disorder symptoms which comprises administering to said human an effective nontoxic generalized antianxiety disorder treatment amount of 9-[3-(3,5-cis-dimethylpiperazino)propyl]carbazole, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1 in which the amount is 0.25 to 15 mg/kg of bodyweight calculated as base.

### Claim 3 (depends on 2)

The method of claim 2 in which the amount is 1 to 10 mg/kg of bodyweight calculated as base.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2 in which said carbazole, salt or solvate are administered in a pharmaceutically acceptable carrier.

### Claim 5

The method of treating a panic disorder in a human which has been identified as exhibiting panic disorder symptoms which comprises administering to said human an effective nontoxic antipanic disorder treatment of 9-[3-3,5-cis-dimethylpiperazino)propyl]carbazole, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The method of claim 5 in which the amount is 0.25 to 15 mg/kg of bodyweight calculated as base.

### Claim 7 (depends on 6)

The method of claim 6 in which the amount is 1 to 10 mg/kg of bodyweight calculated as base.

### Claim 8 (depends on 5, 6)

The method of claim 5 or 6 in which said carbazole, salt or solvate are administered in a pharmaceutically acceptable carrier.

### Claim 9

The method of treating a phobic disorder in a human which has been identified as exhibiting phobic disorder symptoms which comprises administering to said human an effective nontoxic antiphobic disorder treatment amount of 9-[3-(3,5-cis-dimethylpiperazino)propyl]carbazole, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt.

### Claim 10 (depends on 9)

The method of claim 9 in which the amount is 0.25 to 15 mg/kg of bodyweight calculated as base.

### Claim 11 (depends on 10)

The method of claim 10 in which the amount is 1 to 10 mg/kg of bodyweight calculated as base.

### Claim 12 (depends on 9, 10)

The method of claim 9 or 10 in which said carbazole, salt or solvate are administered in a pharmaceutically acceptable carrier.

### Claim 13 (depends on 9, 10)

The method of claim 9 or 10 in which the phobic disorder is Agoraphobia.

### Claim 14

The method of treating post traumatic stress disorder in a human which has been identified as exhibiting post traumatic stress disorder symptoms which comprises administering to said human an effective nontoxic antipost traumatic stress disorder treatment amount of 9-[3-(3,5-cis-dimethylpiperazino)propyl]carbazole, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 4)

The method of claim 4 in which the amount is 0.25 to 15 mg/kg of bodyweight calculated as base.

### Claim 16 (depends on 2)

The method of claim 2 in which the amount is 1 to 10 mg/kg of bodyweight calculated as base.

### Claim 17 (depends on 14, 15)

The method of claim 14 or 15 in which said carbazole, salt or solvate are administered in a pharmaceutically acceptable carrier.

### Claim 18

The method of treating obsessive compulsive disorder in a human which has been identified as exhibiting obsessional compulsive disorder symptoms which comprises administering to said human an effective nontoxic antiobsessive compulsive disorder treatment amount of 9-[3-(3,5-cis-dimethylpiperazino)propyl]carbazole, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The method of claim 18 in which the amount is 0.25 to 15 mg/kg of bodyweight calculated as base.

### Claim 20 (depends on 19)

The method of claim 19 in which the amount is 1 to 10 mg/kg of bodyweight calculated as base.

### Claim 21 (depends on 18, 19)

The method of claim 18 or 19 in which said carbazole, salt or solvate are administered in a pharmaceutically acceptable carrier.

### Claim 22

The method of treating anxiety which is susceptable to treatment in a human which has been identified as exhibiting anxiety symptoms which comprises administering to said human an effective nontoxic antianxiety treatment amount of 9-[3-(3,5-cis-dimethylpiperazino)propyl]carbazole a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 22)

The method of claim 22 in which the amount is 0.25 to 15 mg/kg of bodyweight calculated as base.

### Claim 24 (depends on 23)

The method of claim 23 in which the amount is 1 to 10 mg/kg of bodyweight calculated as base.

### Claim 25 (depends on 22, 23)

The method of claim 22 or 23 in which said carbazole, salt or solvate are administered in a pharmaceutically acceptable carrier.

### Claim 26 (depends on 22)

The method of claim 22 in which the carbazole or salt thereof is administered as part of a tablet or capsule.